These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23873029)

  • 1. Functions of TAp63 and p53 in restraining the development of metastatic cancer.
    Tan EH; Morton JP; Timpson P; Tucci P; Melino G; Flores ER; Sansom OJ; Vousden KH; Muller PA
    Oncogene; 2014 Jun; 33(25):3325-33. PubMed ID: 23873029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype.
    Muller PA; Trinidad AG; Caswell PT; Norman JC; Vousden KH
    J Biol Chem; 2014 Jan; 289(1):122-32. PubMed ID: 24220032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
    Gunaratne PH; Pan Y; Rao AK; Lin C; Hernandez-Herrera A; Liang K; Rait AS; Venkatanarayan A; Benham AL; Rubab F; Kim SS; Rajapakshe K; Chan CK; Mangala LS; Lopez-Berestein G; Sood AK; Rowat AC; Coarfa C; Pirollo KF; Flores ER; Chang EH
    Cancer; 2019 Jul; 125(14):2409-2422. PubMed ID: 31012964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.
    Muller PA; Trinidad AG; Timpson P; Morton JP; Zanivan S; van den Berghe PV; Nixon C; Karim SA; Caswell PT; Noll JE; Coffill CR; Lane DP; Sansom OJ; Neilsen PM; Norman JC; Vousden KH
    Oncogene; 2013 Mar; 32(10):1252-65. PubMed ID: 22580601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.
    Ogata T; Nakamura M; Sang M; Yoda H; Hiraoka K; Yin D; Sang M; Shimozato O; Ozaki T
    PLoS One; 2017; 12(7):e0179884. PubMed ID: 28671946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation.
    Napoli M; Li X; Ackerman HD; Deshpande AA; Barannikov I; Pisegna MA; Bedrosian I; Mitsch J; Quinlan P; Thompson A; Rajapakshe K; Coarfa C; Gunaratne PH; Marchion DC; Magliocco AM; Tsai KY; Flores ER
    Nat Commun; 2020 Oct; 11(1):5156. PubMed ID: 33056990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 drives invasion by promoting integrin recycling.
    Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
    Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-129 targets CDK1 and iASPP to modulate Burkitt lymphoma cell proliferation in a TAp63-dependent manner.
    Zou H; Zou R; Chen K; Zhu C; Tian X; You Y; He X
    J Cell Biochem; 2018 Nov; 119(11):9217-9228. PubMed ID: 30105797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAp63 induces senescence and suppresses tumorigenesis in vivo.
    Guo X; Keyes WM; Papazoglu C; Zuber J; Li W; Lowe SW; Vogel H; Mills AA
    Nat Cell Biol; 2009 Dec; 11(12):1451-7. PubMed ID: 19898465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.
    Su X; Chakravarti D; Cho MS; Liu L; Gi YJ; Lin YL; Leung ML; El-Naggar A; Creighton CJ; Suraokar MB; Wistuba I; Flores ER
    Nature; 2010 Oct; 467(7318):986-90. PubMed ID: 20962848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
    Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
    Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
    Sang M; Nakamura M; Ogata T; Sun D; Shimozato O; Nikaido T; Ozaki T
    Oncol Rep; 2018 Jun; 39(6):2749-2758. PubMed ID: 29620279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
    Xia W; Bai H; Deng Y; Yang Y
    J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
    Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
    Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.
    Godfrey JD; Morton JP; Wilczynska A; Sansom OJ; Bushell MD
    Cell Death Dis; 2018 May; 9(6):644. PubMed ID: 29844410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAp63 plays compensatory roles in p53-deficient cancer cells under genotoxic stress.
    Yao JY; Chen JK
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):310-5. PubMed ID: 21075072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in cancer.
    Muller PA; Vousden KH
    Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins.
    Lu D; Han C; Wu T
    J Biol Chem; 2013 Jul; 288(27):19484-502. PubMed ID: 23687300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
    Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
    Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
    Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
    Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.